Product Description
RO5083945 is a glycoengineered anti EGFR IgG1 mAb exhibiting increased binding affinity for all Fc_RIIIa variants expressed on immune effector cells.
Mechanisms of Action: EGFR Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for RO-5083945](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Colorectal Cancer|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Sarcoma
Phase 1: Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BP28577 | P1 |
Withdrawn |
Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer |
2016-02-01 |
|
2010-022983-11 | P2 |
Terminated |
Colorectal Cancer |
2013-12-19 |
|
BP25438 | P2 |
Completed |
Colorectal Cancer |
2013-12-01 |
45% |
2010-018945-72 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2013-07-30 |